Cannabis Sleep Trial Targets a Common Palliative Care Problem
Sleep disturbance sits near the center of cancer symptom burden, where pain, fatigue, anxiety, nausea, and emotional distress often reinforce one another. In palliative care, that cluster can quickly erode daily function and health-related quality of life, even when the cancer itself is being actively treated or symptom-directed care is already in place. The planned pilot trial from the Ohio State University Comprehensive Cancer Center is built around that reality: if sleep can be improved, the downstream symptom burden may ease as well.
The protocol tests a nightly oral cannabis gummy containing 5 mg THC and 5 mg CBD against usual care in adults newly entering the palliative care clinic who report at least moderate sleep disturbance. The intervention will be taken 1 hour before bedtime for 30 days. Rather than claiming benefit before the first participant is enrolled, the study is framed as a feasibility and safety exercise with preliminary efficacy built in. That is the correct order for a symptom-management question where the signal is biologically plausible but the evidence base remains thin.
Sleep is the most commonly reported reason adults with cancer use cannabis. The protocol is trying to convert that widespread self-directed practice into structured clinical evidence.
Why Sleep Disturbance in Cancer Demands a Dedicated Trial
The background for the study is stark: sleep disturbance affects 60% of cancer patients, roughly three times the rate seen in the general population. In practice, disturbed sleep is rarely an isolated complaint. It often grows out of physical symptoms, psychological distress, and treatment effects, then feeds back into fatigue, mood symptoms, and pain sensitivity. Once that cycle starts, patients can feel as if they are chasing relief from one symptom only to aggravate another.
Cannabinoids are a reasonable candidate for study because they can influence multiple pathways relevant to symptom burden, including sleep initiation, perceived relaxation, and symptom coping. Yet the clinical literature supporting cannabis for cancer-related symptom control remains limited, especially in rigorously monitored randomized trials. A protocol like this matters because it does not assume the answer. It asks whether a carefully dosed, standardized oral product can be delivered safely and whether patients will actually tolerate and use it in a palliative care setting.
The design also reflects an important bedside concern: sleep complaints in cancer are not abstract quality-of-life metrics. They affect daytime alertness, symptom perception, and the ability to engage with treatment decisions. A therapy that improves sleep without worsening cognition, dizziness, or other adverse effects could be useful; a therapy that disrupts functioning would fail even if patients liked the idea of it.
A 30-Day Oral Gummy, Monitored in Real Time
The planned study will enroll 50 patients from the OSUCCC palliative care clinic, with enrollment anticipated in fall 2026. Eligible participants must be new to the clinic and must report at least moderate sleep disturbance. Randomization will be stratified by sex and race, a design choice intended to support balance across key participant characteristics in a small pilot cohort.
Participants will receive either usual care or the active intervention: a nightly oral gummy containing THC and CBD in equal 5 mg doses. Dosing 1 hour before bedtime is meant to align the pharmacologic window with sleep onset, while the oral formulation offers a standardized route that is more practical for a controlled trial than ad hoc cannabis products of uncertain composition. The 30-day duration is short enough to test early tolerability and adherence, yet long enough to observe whether sleep patterns begin to shift in a meaningful way.
A brief pilot will not answer every clinical question, and it should not pretend to. It can, however, reveal whether patients will accept the intervention, whether adverse events cluster early, and whether sleep-related outcomes move in a direction worth pursuing in a larger trial.
Measuring Sleep, Quality of Life, and Symptom Burden From Multiple Angles
The trial uses a layered assessment strategy. Sleep, HRQOL, and related symptoms will be captured through self-reported questionnaires, ecological momentary assessments, and actigraphy. Each method offers a different window into the same problem. Questionnaires capture the patient’s overall experience; ecological momentary assessment can track symptoms in near real time rather than relying only on recall; and actigraphy supplies an objective measure of sleep-wake activity.
That combination is particularly well suited to a cannabis study, where perceived benefit and measurable sleep change may not always move in lockstep. If a participant feels less disrupted overnight but objective rest patterns remain unchanged, the discrepancy itself can be informative. If both subjective and objective measures improve, the case for a larger efficacy trial becomes stronger. Either way, the protocol avoids reducing sleep to a single number.
Adverse events will be monitored throughout the study. In a palliative care population, safety surveillance is not a footnote. Sedation, balance problems, mood effects, and other tolerability issues can alter the real-world value of any sleep aid, especially one with psychoactive potential.
What This Pilot Can and Cannot Establish
This study is designed to provide safety, feasibility, and preliminary efficacy data, not definitive proof of benefit. A 50-patient single-center pilot cannot settle whether cannabis should become routine treatment for cancer-related sleep disturbance. It can, however, answer the practical questions that determine whether a definitive trial is worth pursuing: Can patients be recruited from a palliative care clinic? Will they accept a nightly cannabis gummy? Can the intervention be delivered consistently over 30 days? Do adverse events remain manageable? Do sleep and quality-of-life measures move in a clinically meaningful direction?
Those questions are especially important because cannabis use for sleep is already common among adults with cancer, even as formal evidence lags behind patient behavior. A controlled protocol gives clinicians a way to move beyond anecdote and toward a more reliable risk-benefit conversation. It also creates a pathway for future multisite research if the pilot is favorable.
The planned readout will not close the chapter on cannabis in supportive oncology. It will, instead, define whether a larger trial is feasible and whether a THC-CBD gummy deserves a place in that next, more demanding test.